Recent News & Research


Structure-based classification predicts drug response in EGFR-mutant NSCLC

*September 2021* Epidermal growth factor receptor (EGFR) mutations typically occur in exons 18–21 and are established driver mutations in non-small cell lung cancer (NSCLC)1,2,3. Targeted therapies are approved for patients with ‘classical’ mutations and a small number of other mutations4,5,6. However, effective therapies have not been identified for additional EGFR mutations. Furthermore,…
November 11, 2021

Words Matter

*September 2021* EGFR Resisters co-founder Jill Feldman presented how stigmatizing words can affect patients and their families at WCLC 2021. Watch the video presentation here.
November 11, 2021